NF-κB signaling regulates myelination in the CNS

Thomas Blank1 and Marco Prinz1,2 *

1 Institute of Neuropathology, University of Freiburg, Freiburg, Germany
2 BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany

INSULATING AXONS VIA OLIGODENDROCYTES

Oligodendrocytes are specialized cells in the CNS that wrap multiple axons with myelin, forming as many as 40 separate myelin segments (Salzer, 2003). This specialization of glial cells was the last major phylogenetical invention for the nervous system of vertebrates (Zalc et al., 2008). A series of stages that result from reciprocal, axo-glial interactions are necessary for the development of myelinated fibers. For the initial step of myelin formation, immature post-mitotic oligodendrocytes need to extend numerous cytoplasmic protrusions (filopodia) in order to find suitable myelin-competent axons. As microfilament-rich filipodia extend, they are invaded by microtubules, thus further enlarging these processes and converting them to lamellipodia. The oligodendrocyte cytoskeleton now increases microfilament polymerization and branching in response to axonal signals. The majority of axonal signals identified to date is expressed to prevent the initiation of myelination and/or exuberant over-myelination. One example includes axonal PSA-NCAM, which is developmentally downregulated to coincide with the onset of myelination (Decker et al., 2000; Fewou et al., 2007). To ensure that glial numbers are matched to axon length, axon outgrowth regulates gliogenesis via mitogenic and trophic effects (Barres and Raff, 1999). But interactions between axonal ligands and glial receptors have to be integrated to modulate myelination and myelin thickness. But what are the exact signals? The protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1 (SHP-1) is a critical regulator of developmental signals leading to terminal differentiation and myelin sheath formation by oligodendrocytes; Figure 1). The SHP-1 homolog, SHP-2, regulates oligodendrocyte progenitor proliferation (Kuo et al., 2010). ErbB, the neuronal growth factor receptor of Neuregulin-1 (NRG-1), affects oligodendrocyte specification after binding to its receptor (Figure 1). It further regulates differentiation, myelination, and survival, at least in vitro (Canoll et al., 1996; Vartanian et al., 1997; Calaora et al., 2001). The situation in vivo is more complex. Only minor effects on overall myelination in the CNS of mice were reported for knockout of NRG1, whereas a significant hypermyelination was achieved by transgenic overexpression of NRG1 (Brinkmann et al., 2008). However, in a more recent study, hypomyelination and thinner myelin sheaths were found in the prefrontal cortex when NRG-1 signaling was disturbed (Makinodan et al., 2012). It should be mentioned that neuronal activity can regulate NRG-1 levels thus linking it to myelin production (Ziskin et al., 2007; Liu et al., 2011). Myelin sheaths are radially organized with distinct proteins in the abaxonal (e.g., oligodendrocyte myelin glycoprotein) and inner glial (e.g., MAG and NCAM) membranes.

Myelination of axons allows for the process of salutary conduction, in which a neuronal action potential is propagated between nodes of Ranvier to increase both the speed and energy efficiency of nerve conduction. The generation of action potentials (AP) is possible due to the accumulation of voltage gated sodium channels, Na+/K+ ATPases, Na+/Ca2+ antiporters, as well as specific subtypes of potassium channels important for the regulation of repetitive discharges (Devaux et al., 2004; Pan et al., 2006). Myelination also markedly decreases the refractory time (time needed for repolarization before a new AP can be supported by the axon; Felts et al., 1997; Sinha et al., 2006). Qualitative differences of myelination along axons, such as variations in internode distance and myelin sheath thickness, enable systematic regulation of conduction velocity. Myelination sometimes ensures that axons of different length have isochronous conduction times, enabling them to activate their synaptic targets simultaneously. Two examples include the projections of retinal ganglion neurons to the lateral geniculate (Stanford, 1987) and projections of inferior olivary neurons to Purkinje cells in the cerebellar cortex (Sugihara et al., 1993). Thus, intact myelin enhances the integration of information across spatially distributed neural networks supporting...
Cognitive and motor functions (Bartzokis et al., 2001; Lutz et al., 2005). There is further increasing evidence that oligodendrocytes provide trophic support to axons and promote their viability. These mechanisms may include metabolic coupling, with oligodendrocytes providing axons with lactate as an energy source via the lactate transporter monocarboxylate transporter 1 (MCT1, also known as SLC16A1; Funfschilling et al., 2012; Lee et al., 2012b).

Nuclear factor-κB is a ubiquitously expressed dimeric molecule that regulates the expression of a variety of genes and has a key role in a number of cellular processes such as innate and adaptive immunity, cellular proliferation, apoptosis, and development. Often diseases involving oligodendrocytes are associated with NF-κB activation causing some degree of demyelination. Whether this effect is of direct nature or indirect via surrounding cells and the potential contribution of NF-κB to phenomena like myelination and remyelination will be carefully highlighted and discussed in the following paragraphs.

**IS NF-κB ESSENTIAL FOR MYELINATION IN THE CNS?**

Originally identified as a transcription factor that regulates expression of the immunoglobulin kappa light chain gene in...
response to cytokine stimulation in B lymphocytes, NF-κB is now known to be expressed in most, if not all, mammalian cells. Five subunits, p50, p52, p65 (RelA), RelB, and c-Rel, form homo and heterodimers (Karin and Lin, 2002; Yan and Greer, 2008). In an inactive state, NF-κB dimers are sequestered in the cytoplasm by the specific inhibitors IκBα, IκBβ, and IκBe. On stimulation, IκB is phosphorylated by the IκB kinase (IKK) complex, ubiquitinated, and then degraded by the 26S proteasome. The IKK complex contains two enzymatic subunits, IKK1 (also known as IκKa) and IKK2 (also known as IκKB), with partially overlapping substrate specificity. IKK2 is required for NF-κB activation through the canonical pathway triggered by proinflammatory stimuli. These diverse stimuli that activate NF-κB do not only include inflammatory cytokines such as tumor necrosis factor-α (TNF-α) but also neurotrophic factors such as nerve growth factor (NGF), neurotransmitters, cell adhesion molecules and various types of cell stress (Mattson and Camandola, 2001; Karin and Lin, 2002). Genes that can be induced by NF-κB include those that encode cytokines such as TNF-α and interleukin-1β, interleukin 6, the antioxidant enzyme manganese superoxide dismutase, and the anti-apoptotic protein Bcl-2 (Mattson and Camandola, 2001).

At present, there is ongoing controversial discussion about the contribution of NF-κB to myelin production in the CNS. In a recent study it was shown that in patients with additional copies of the IκKBα gene, which encodes for NF-κB essential modulator (NEMO), the regulatory subunit of the IKK complex, NF-κB signaling is impaired. These patients showed defective myelination, developmental brain abnormalities and mild mental retardation (Philippe et al., 2013). From these findings it was concluded that proper myelination in the CNS requires NF-κB activation. However, several transgenic mouse studies seem to exact the opposite. When the NF-κB subunit RelA was almost completely deleted from the mouse CNS, histological and electron microscopic analyses showed unimpaired oligodendrocyte densities and normal myelin sheath formation (Kretz et al., 2014). Accordingly, mice with inactivated NF-κB by either overexpression of the super repressor IκBα or deletion of the activator IκKB in the neuroglial compartment develop normally and display no alterations in overall neuro-anatomical and behavioral features (Herrmann et al., 2005; Zhang et al., 2005). There is further evidence that IκKB-mediated NF-κB activation is dispensable for oligodendrocyte maturation in vitro and in vivo, and subsequent insulation of axons in the CNS (Raasch et al., 2011). These results are either in sharp contrast to the reported crucial role of NF-κB signaling for myelination in the PNS (Nickols et al., 2003), or display a similar picture as seen in mice with ablated IκKB in Schwann cells, where NF-κB activation was described as dispensable for myelination (Morton et al., 2013). Since the study by Nickols et al. (2003) was solely performed using cultured neurons, a possible explanation for the discrepancy between these findings might be that Schwann cells simply behave differently in vitro and in vivo. Thus, NF-κB signaling appears expendable for myelination in the PNS and CNS.

NF-κB, DE-AND REMYELINATION IN THE CNS

Among the NF-κB family members only deletion of p50 results in spontaneous demyelination in young adult animals (Lu et al., 2006). Electron microscopy revealed an age-dependent reduction in the number of axons and degenerative alterations in the optic nerve of both wild type and p50−/− mice. P50−/− knockout markedly accelerated the axonal reduction and degeneration more likely due to demyelination as well as axonal degeneration. This effect on myelination or axonal degeneration cannot be explained by reduced NF-κB activity since p50 deficiency in mice enhances NF-κB activity (Schmitz and Baeuerle, 1991; Tang et al., 2010). Accordingly, in mice with conditional neuronal NF-κB ablation, the clinical course of experimental autoimmune encephalomyelitis (EAE), a well-characterized animal model mimicking multiple sclerosis in humans, parameters of inflammation and axonal densities in the spinal cord white and gray matter were not different to littermate controls (Lee et al., 2012a). In a similar approach using genetically engineered mice, a cell type specific knockout of NF-κB essential modulator (NEMO) or IκBα-kinase-complex (IKK)-2 with Nestin promoter-driven Cre expression ameliorated EAE (van Loo et al., 2006). Here the NF-κB regulated expression of pro-inflammatory cytokines and cell adhesion molecules in astrocytes rather than effects in neurons were found essential for the propagation of EAE. In the only real contrasting study a neuroprotective effect of neuronal IKK-2 in autoimmune demyelination was reported (Emmanouil et al., 2011). It cannot be excluded that the observed effects are due to potentially other, so far unknown, phosphorylation targets of IKK-2 than IκB. In vitro studies have shown that NF-κB exhibits a pro-survival role in a rat oligodendrocyte precursor cell line, with p50 being more effective than p65 to prevent TNF-α-induced apoptosis (Hamanoue et al., 2004). NF-κB further promotes survival and maturation of oligodendrocyte progenitor cells in vitro (Nicholas et al., 2001), a finding that was not apparent by our in vivo study where we found a normal number of mature oligodendrocytes in the adult corpus callosum of IKK2-deficient brains (Raasch et al., 2011). Importantly, brain-specific IKK2-dependent NF-κB signaling has an essential role during toxin-induced demyelination in vivo. The amelioration of demyelination in mice with brain-restricted NF-κB inhibition correlated with impaired induction of inflammatory cytokines, which are potentially toxic for oligodendrocytes. This protection against demyelination was mediated through ablation of IKK2 from astrocytes but not from oligodendrocytes (Raasch et al., 2011). Astrocytic NF-κB inhibition would also diminish expression of A disintegrin and metalloproteinase (ADAM) 12, which showed elevated expression especially in brain regions affected by oligodendrocyte loss (Baertling et al., 2010). An increased number of ADAM12-positive astrocytes was for example observed after the induction of toxic demyelination by cuprizone feeding. Whether this is ultimately of detrimental or supportive nature for oligodendrocytic function has to be determined. ADAM12 has been shown to cleave insulin-like growth factor-2 binding protein-3 (Shi et al., 2000). This protein is obviously functionally related to the development of oligodendrocytes and the formation and/or regeneration of the myelin sheath (Mewar and McMorris, 1997; Lovett-Racke et al., 1998). At present, however, it remains elusive which functions ADAM12 takes over during de- and remyelination.
Astrocytic, but not microglial NF-κB inhibition was also responsible for remyelination during cuprizone-induced demyelination by the new oral immunomodulatory compound Laquinimod (LAQ; Bruck et al., 2012). This finding might seem surprising considering that during cuprizone-induced demyelination NF-κB was activated not only in astrocytes but also in microglia (Millet et al., 2009). Indeed, mice with a selective inactivation of the NF-κB pathway in microglia were substantially protected from the induction of EAE (Goldmann et al., 2013). The loss of oligodendrocytes may be replaced by proliferating nerve/glial antigen 2 (NG2) cells, also known as oligodendrocyte precursor cells (Tripathi and McTigue, 2007). These OPCs are able to mingle with the damaged site and differentiate into mature myelinating oligodendrocytes if the environment is permissive (Franklin and French-Constant, 2008). For instance, degenerated myelin contains inhibitory molecules such as Nogo-A, Oligodendrocyte-myelin glycoprotein (OMgp) and myelin-associated glycoprotein (MAG). Degenerated myelin further activates the FAK/PI3K/Akt/NF-κB pathway in macrophages and increases the expression of inflammatory mediators (Sun et al., 2010). These factors inhibit axon regeneration and further activate complement systems to destroy intact myelin (McKerracher et al., 1994; Chen et al., 2000). In transgenic mice with NF-κB inhibition specifically in astrocytes an increase in oligodendrogenesis was observed following spinal cord injury (Bracchi-Ricard et al., 2013). The same mice were significantly protected against optic neuritis and showed a nearly complete prevention of axonal demyelination, as well as a drastic attenuation in retinal ganglion cell death (Brambilla et al., 2012). Following EAE induction, Nos2 and the NAD(P)H oxidase subunits Cybb/NOX2 and Ncf1 were upregulated in WT mice but not in GFAP-IκBα−/− mice, where NF-κB is selectively inactivated in astrocytes. On the other hand, activation of the NF-κB pathway in oligodendrocytes contributes to the protective effects of enhanced pancreatic endoplasmic reticulum kinase (PERK) signaling during EAE including reduced oligodendrocyte apoptosis, demyelination, and axonal degeneration (Deng et al., 2004). PERK signaling activates NF-κB, an antiapoptotic transcription factor, by repressing the translation of IκBα, an inhibitor of NF-κB (Lin et al., 2013).

These GFAP-IκBα−/− mice showed not only preservation of myelin compaction but also enhanced remyelination during recovery from EAE due to reduced expression of pro-inflammatory genes (Brambilla et al., 2014). In the same line, activation of NF-κB within astrocytes resulted in a significant increase in oligodendrocyte death following trauma by reducing extracellular zinc levels and inducing glutamate excitotoxicity (Johnstone et al., 2013). These results are consistent with several in vitro studies which indicated that astrocytes can directly modulate myelination via the release of a number of secreted factors, depending on culture conditions (Moore et al., 2011; Nash et al., 2011). From the in vivo data, however, it could not be determined whether the decreased expression of an NF-κB-regulated gene has a direct effect on oligodendrocyte maturation or an indirect effect through other cells such as microglia and/or infiltrating macrophages. Indeed, it was speculated that inhibiting astrogial NF-κB affects the activation status of microglia/macrophages rendering them more supportive for remyelination. From in vitro experiments it was reported that non-activated microglia activate NF-κB in OPCs thereby increasing the number of surviving oligodendrocytes by inhibiting the apoptosis of OPCs and stimulating their maturation to oligodendrocytes (Nicholas et al., 2001). In accordance, when mice were fed cuprizone together with low concentrations of lactacystin, a specific inhibitor of the 26S proteasome, they showed a decrease in activated microglia response with a markedly diminished NF-κB activation during their remyelination period when compared to mice fed cuprizone only (Millet et al., 2009). Ineffective remyelination is often caused by the presence of differentiation inhibitors in the vicinity of oligodendrocyte damage, which include cytokines and chemokines, many of which are regulated by NF-κB (Kotter et al., 2006; Kremer et al., 2011). Although NF-κB might also support the remyelination process via TNF, a prototypical inducer of NF-κB, which is required for both remyelination and proliferation of OPCs (Arnett et al., 2001; Figure 1), we found no active role for oligodendrocyte-specific IKK2 during remyelination (Raasch et al., 2011). Inhibition of NF-κB in Schwann cells also seems to have no major impact on remyelination except for transiently slowing down the whole process (Morton et al., 2012).

Taken together, the present data suggest no direct contribution of the oligodendrocytic NF-κB pathway to myelination, demyelination and remyelination. Activation of astrocytic and microglial NF-κB, however, seems to favor demyelination whereas its inhibition supports remyelination. Activation of NF-κB in OPCs increases the number of surviving oligodendrocytes and stimulates their maturation to oligodendrocytes which effects myelination and remyelination.

ACKNOWLEDGMENTS

Marco Prinz is supported by the DFG funded research unit (FOR) 1336, the BMBF-funded Competence Network of Multiple Sclerosis (KKNMS), the Competence Network of Neurodegenerative Disorders (KNDD), and the DFG (PR 577/8-2). We are grateful to Stefanie Breendecke and Tobias Goldmann for critically reading the manuscript.

REFERENCES

Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsuhashima, G. K., and Ting, J. P. (2001). TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116–1122. doi: 10.1038/nn738

Baerling, F., Kokozidou, M., Pufe, T., Clarner, T., Windoffer, R., Wruck, C. J., et al. (2010). ADAM12 is expressed by astrocytes during experimental demyelination. Brain Res. 1326, 1–14. doi: 10.1016/j.brainres.2010.02.049

Barres, B. A., and Raff, M. C. (1999). Axonal control of oligodendrocyte development. J. Cell Biol. 147, 1123–1128. doi: 10.1083/jcb.147.6.1123

Bartozikis, G., Beckson, M., Lu, P. H., Nuechterlein, K. H., Edwards, N., and Mintz, J. (2001). Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch. Gen. Psychiatry 58, 461–465. doi: 10.1001/archpsyc.58.5.461

Bracchi-Ricard, V., Lambertsen, K. L., Ricard, J., Nathanson, L., Karmally, S., Johnstone, J., et al. (2013). Inhibition of astroglial NF-kappaB enhances oligodendrogenesis following spinal cord injury. J. Neuroinflammation 10, 92. doi: 10.1186/1742-2094-9-92

Brambilla, R., Dvoriantchikova, G., Barakat, D., Ivanov, D., Bethea, J. R., and Shestopalov, V. I. (2012). Transgenic inhibition of astroglial NF-kappaB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis. J. Neuroinflammation 9, 213. doi: 10.1186/1742-2094-9-213
Morton, P. D., Johnstone, J. T., Ramos, A. Y., Liebl, D. J., Bunge, M. B., and Bethea, J. R. (2012). Nuclear factor-kappaB activation in Schwann cells regulates regeneration and remyelination. *Glia* 60, 639–650. doi: 10.1002/glia.22297

Nash, B., Thomson, C. E., Linnington, C., Arthur, A. T., McClure, J. D., McBride, M. W., et al. (2011). Functional duality of astrocytes in myelination. *J. Neurosci.* 31, 13028–13038. doi: 10.1523/JNEUROSCI.1449-11.2011

Nicholas, R. S., Wang, M. G., and Compston, A. (2001). Nonactivated microglia promote oligodendrocyte precursor survival and maturation through the transcription factor NF-kappa B. *Eur. J. Neurosci.* 13, 959–967. doi: 10.1046/j.0953-816x.2001.01470.x

Nickols, J. C., Valentine, W., Kanwal, S., and Carter, B. D. (2003). Activation of the transcription factor NF-kappaB in Schwann cells is required for peripheral myelin formation. *Nat. Neurosci.* 6, 161–167. doi: 10.1038/nn995

Pan, Z., Kao, T., Horvath, Z., Lemos, J., Sul, J. Y., Cranston, S. D., et al. (2006). A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. *J. Neurosci.* 26, 2599–2613. doi: 10.1523/JNEUROSCI.4314-05.2006

Philippe, O., Rio, M., Malan, V., Van Esch, H., Baujat, G., Bahi-Buisson, N., et al. (2011). Functional duality of astrocytes in myelination. *CNS Neurol. Disord. Drug Targets* 7, 954–961. doi: 10.1083/nu1372

Raasch, J., Zeller, N., Van Loo, G., Merkler, D., Mildner, A., Erny, D., et al. (2011). IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. *Brain* 134, 1184–1198. doi: 10.1093/brain/aws359

Salzer, J. L. (2003). Polarized domains of myelinated axons. *Neuron* 40, 297–318. doi: 10.1016/S0896-6273(03)00627-7

Schmitz, M. L., and Baeuerle, P. A. (1991). The p65 subunit is responsible for the strong transcription activating potential of NF-kappaB. *J. Biol. Chem.* 266, 3573–3578. doi: 10.1016/0308-2011(91)90140-J

Shi, Z., Xu, W., Loechel, F., Wewer, U. M., and Murphy, L. J. (2000). Vesicular release of glutamate from unmyelinated axons in white matter. *Neuron* 27, 18574–18580. doi: 10.1016/S0896-6273(00)00627-7

Sun, X., Wang, X., Chen, T., Li, T., Cao, K., Lu, A., et al. (2010). Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. *PLoS ONE* 5:e9380. doi: 10.1371/journal.pone.0009380

Tang, T., Zhang, J., Yin, J., Staszkiewicz, J., Gaswrona-Kozak, B., Jung, D. Y., et al. (2010). Uncoupling of inflammation and insulin resistance by NF-kappaB in transgenic mice through elevated energy expenditure. *J. Biol. Chem.* 285, 4637–4644. doi: 10.1074/jbc.M109.068007

Tripathi, R., and McTigue, D. M. (2007). Prominent oligodendrocyte genesis along the border of spinal contusion lesions. *GLIA* 55, 698–711. doi: 10.1002/glia.20491

van Loo, G., De Lorenzi, R., Schmidt, H., Huth, M., Mildner, A., Schmidt-Supprian, M., et al. (2006). Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. *Nat. Immunol.* 7, 954–961. doi: 10.1038/ni1372

Vartanian, T., Goodarzi, A., Viehover, A., and Fischbach, G. (1997). Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. *J. Cell Biol.* 137, 211–220. doi: 10.1083/jcb.137.1.211

Yan, J., and Greer, J. M. (2008). NF-kappaB, a potential therapeutic target for the treatment of multiple sclerosis. *CNS Neurol. Disord. Drug Targets* 7, 536–557. doi: 10.2174/187152708787122941

Zalc, B., Goujet, D., and Colman, D. (2008). The origin of the myelination program in vertebrates. *Curr. Biol.* 18, R511–R512. doi: 10.1016/j.cub.2008.04.010

Zhang, W., Potrovita, I., Tarabini, V., Herrmann, O., Beer, V., Weih, F., et al. (2005). Neuronal activation of NF-kappaB contributes to cell death in cerebral ischemia. *J. Cereb. Blood Flow Metab.* 25, 30–40. doi: 10.1038/sj.jcbfm.9600004

Ziskin, J. L., Nishiyama, A., Rubio, M., Fukaya, M., and Bergles, D. E. (2007). Vesicular release of glutamate from unmyelinated axons in white matter. *Nat. Neurosci.* 10, 321–330. doi: 10.1038/nn1854

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.